Israeli biotech Gamida Cell (see here) published positive results in its Phase 3, 50-center trial of NiCord (now called Omidubicel) that aims to increase the success of bone marrow transplants in blood cancer patients. The stem cells were established much quicker than alternatives.

https://www.timesofisrael.com/cell-therapy-firm-boosts-odds-for-blood-cancer-patients-as-key-trial-succeeds/